The problem with antibiotics

Publikation: Bidrag til tidsskrift › Letter › Forskning

Standard

The problem with antibiotics. / Darrow, Jonathan; Minssen, Timo.

I: The Economist, Bind 431, Nr. 9144, 05.2019, s. 20.

Publikation: Bidrag til tidsskrift › Letter › Forskning

Harvard

Darrow, J & Minssen, T 2019, 'The problem with antibiotics', The Economist, bind 431, nr. 9144, s. 20. <https://www.economist.com/letters/2019/05/25/letters-to-the-editor >

APA

Darrow, J., & Minssen, T. (2019). The problem with antibiotics. The Economist, 431(9144), 20. https://www.economist.com/letters/2019/05/25/letters-to-the-editor

Vancouver

Darrow J, Minssen T. The problem with antibiotics. The Economist. 2019 maj;431(9144):20.

Author

Darrow, Jonathan ; Minssen, Timo. / The problem with antibiotics. I: The Economist. 2019 ; Bind 431, Nr. 9144. s. 20.

Bibtex

@article{80007404d3764f4a89cbbdf66c9f7af9,
title = "The problem with antibiotics",
abstract = " While greater incentives and new funding models for antibiotic drug develooment are needed, it is unclear whether a system dependent on endlessly churning out new and ever more expensive medicines will be  economically feasible and scientifically possible in the long term. Greater priority should therefore be given to implementing more permanent solutions that are not limited to slowing resistance, which at best merely shifts the problem from today{\textquoteright}s generation to the next, an ethically murky result. While no single approach is likely to be sufficient, governments should begin by reviving the moribund vision of using the vaccines, treatments, and other tools that are already at hand to eradicate disease and thereby stop -- not slow -- the development of resistance. Due to non-human disease vectors and other challenges, eradication may not currently be possible for every disease, but for those diseases amenable to it, the window of opportunity may fast be closing. ",
keywords = "Faculty of Law, vaccines, antimicrobials, resistance, incentives, law, regulation",
author = "Jonathan Darrow and Timo Minssen",
year = "2019",
month = may,
language = "English",
volume = "431",
pages = "20",
journal = "The Economist",
issn = "1821-3715",
publisher = "Color Press Grupa",
number = "9144",

}

RIS

TY - JOUR

T1 - The problem with antibiotics

AU - Darrow, Jonathan

AU - Minssen, Timo

PY - 2019/5

Y1 - 2019/5

N2 -  While greater incentives and new funding models for antibiotic drug develooment are needed, it is unclear whether a system dependent on endlessly churning out new and ever more expensive medicines will be  economically feasible and scientifically possible in the long term. Greater priority should therefore be given to implementing more permanent solutions that are not limited to slowing resistance, which at best merely shifts the problem from today’s generation to the next, an ethically murky result. While no single approach is likely to be sufficient, governments should begin by reviving the moribund vision of using the vaccines, treatments, and other tools that are already at hand to eradicate disease and thereby stop -- not slow -- the development of resistance. Due to non-human disease vectors and other challenges, eradication may not currently be possible for every disease, but for those diseases amenable to it, the window of opportunity may fast be closing. 

AB -  While greater incentives and new funding models for antibiotic drug develooment are needed, it is unclear whether a system dependent on endlessly churning out new and ever more expensive medicines will be  economically feasible and scientifically possible in the long term. Greater priority should therefore be given to implementing more permanent solutions that are not limited to slowing resistance, which at best merely shifts the problem from today’s generation to the next, an ethically murky result. While no single approach is likely to be sufficient, governments should begin by reviving the moribund vision of using the vaccines, treatments, and other tools that are already at hand to eradicate disease and thereby stop -- not slow -- the development of resistance. Due to non-human disease vectors and other challenges, eradication may not currently be possible for every disease, but for those diseases amenable to it, the window of opportunity may fast be closing. 

KW - Faculty of Law

KW - vaccines

KW - antimicrobials

KW - resistance

KW - incentives

KW - law

KW - regulation

M3 - Letter

VL - 431

SP - 20

JO - The Economist

JF - The Economist

SN - 1821-3715

IS - 9144

ER -

ID: 217616129